Group 1 - Hualing Cable recently won multiple contracts totaling approximately 557 million yuan, accounting for 13.40% of its audited revenue for 2024 [1] - The projects include contracts from Southern Power Grid, China Institute of Atomic Energy, Zijin Mining, Tianjin Rail Transit, and China Nonferrous Metal International Mining [1] Group 2 - Weisi Medical's shareholder plans to reduce its stake by up to 3%, totaling no more than 2.8731 million shares, due to personal funding needs [2] - Han Yi Co. intends to invest 102 million yuan to acquire a 39% stake in Shanghai Pidong Cultural Media, aiming to expand its IP derivative business [2] Group 3 - Zhongsheng High-Tech's controlling shareholder will change to Fuzhou Qianjing after signing a share transfer agreement, with stock resuming trading [3] - Tianli Lithium Energy plans to invest 30% in a joint venture for advanced energy research, contributing 30 million yuan [5] Group 4 - Zhenbang Intelligent plans to invest up to 11 million USD to establish a production base in Indonesia [8] - Shenhuo Co. aims to set up a 1.512 billion yuan industry fund focusing on strategic emerging industries [9] Group 5 - Shenhuo Co. intends to acquire a 14.69% stake in Shenhuo New Materials for 298 million yuan through public bidding [11] - Kema Technology plans to acquire a 73% stake in Suzhou Kaixin Semiconductor for 102 million yuan to enhance its capabilities in silicon carbide materials [13] Group 6 - China Power Construction's subsidiary won two major engineering projects with total contract values of approximately 57.52 billion yuan and 54.39 billion yuan [14] - Huaxin Environmental plans to reduce its stake by up to 1.58% due to personal funding needs [15] Group 7 - Yuandong Bio's shareholders plan to collectively reduce their stake by up to 1.91% for personal funding needs [17] - Xiangming Intelligent's controlling shareholder plans to reduce its stake by up to 3% due to personal funding needs [18] Group 8 - Sand Technology's actual controller's associates plan to reduce their stake by up to 2% for personal funding needs [19] - Beifang Changlong decided to terminate the acquisition of 51% of Henan Zhongzheng due to changes in market conditions [20] Group 9 - ST Huicheng plans to publicly transfer 30% of its subsidiary Peak Intelligent for a starting price of 5.1 million yuan [22] - Yunji Group's major shareholder plans to reduce its stake by up to 3% for personal funding needs [23] Group 10 - Shunbo Alloy plans to raise up to 600 million yuan through a private placement to enhance its main business [24] - Berry Gene's major shareholder will face judicial enforcement on 1% of its shares due to a pledge default [25] Group 11 - Guanglian Aviation's controlling shareholder is under investigation, but the company's operations remain normal [26]

Core Viewpoint - The announcement details the forced liquidation of shares held by major shareholder Mr. Gao Yang due to a default in a stock pledge repurchase agreement with Guoxin Securities, which has been ruled by the Chengyu Financial Court [1][2]. Group 1: Shareholder Information - Mr. Gao Yang holds 28,453,510 shares of Berry Genomics, accounting for 8.05% of the company's total share capital [1]. - The shares being executed amount to 3,535,214 shares, which are part of the stock pledged in a dispute with Guoxin Securities [1][2]. Group 2: Share Lock-up and Compliance - The shares subject to forced execution were acquired by Mr. Gao during a major asset restructuring transaction involving the purchase of 100% equity of Berry Genomics [2]. - Mr. Gao had previously committed to a lock-up period for these shares, which has now expired as the shares have been held for over 36 months without triggering any extension conditions [3]. Group 3: Legal and Regulatory Compliance - The forced execution of shares does not violate any previously disclosed holding intentions or commitments made by Mr. Gao [3]. - The company will ensure compliance with relevant laws and regulations during the execution process and will disclose any progress as required [3].

Summary of Key Points Core Viewpoint - The announcement details a significant change in shareholding for Chengdu Berry Genomics Co., Ltd. due to stock pledge defaults by a major shareholder, resulting in forced sales of shares through judicial auction [1]. Group 1: Shareholding Changes - The controlling shareholder, Gao Yang, had 157,230 shares sold, representing 0.04% of the total share capital, due to a stock pledge default [1]. - A total of 13,785,075 shares held by the associated party, Hou Ying, were auctioned, with 8,656,886 shares transferred on July 21, 2025, accounting for 2.45% of the total share capital [1]. - The total shares reduced by both Gao Yang and Hou Ying amounted to 8,814,116 shares, which is 2.49% of the total share capital [1]. Group 2: Shareholding Structure Post-Change - After the changes, the total shares held by the company decreased from 42,395,815 shares (11.99%) to 33,581,699 shares (9.50%) [2]. - The number of unrestricted shares held dropped from 18,404,273 shares (5.21%) to 9,590,157 shares (2.71%), while the restricted shares remained unchanged at 23,991,542 shares (6.79%) [2]. - The company confirmed that the judicial enforcement and auction did not adversely affect its operational or financial status, nor its governance structure [2].

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-036 成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行的提示性公告 股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、高扬先生持有成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或 "贝瑞基因"）股份 28,453,510 股（占公司总股本比例为 8.05%），为公司控股股 东。现因高扬先生在国信证券股份有限公司（以下简称"国信证券"）开展的股票质 押回购业务发生违约，成渝金融法院裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。 2、公司目前生产经营情况正常，该事项未对公司的生产经营及财务状况产生重 大不利影响，未对公司治理结构产生重大不利影响。 公司于近日收到股东高扬先生通知，其于近日收到成渝金融法院作出的(2024) 渝 87 执 4703 号之五《执行裁定书》，裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。现将有关情况 ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-037 成都市贝瑞和康基因技术股份有限公司 关于控股股东及其一致行动人权益变动触及1%整数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 控股股东高扬先生及一致行动人侯颖女士保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因"或"公司"） 于近日接到控股股东之一致行动人侯颖女士所持有股份发生变动的通知，现将本 次权益变动的具体情况公告如下： | 1．基本情况 | | | | | --- | --- | --- | --- | | 信息披露义务人 | 高扬 | | | | | | 侯颖（高扬之一致行动人） | | | 住所 | | 北京市昌平区科技园区生命园路 4 号院 5 号楼 | | | 权益变动时间 | 2025 | 年 5 月 23 | 日-2025 年 7 月 21 日 | | 权益变动过程 | 司在 | 2025 年 5 本 ...

Core Viewpoint - The major shareholder Gao Yang of Berry Genomics (000710.SZ) is facing judicial enforcement for the forced liquidation of 3,535,214 shares, representing 1% of the company's total equity, due to a breach of contract in a stock pledge repurchase agreement [1] Group 1 - The forced liquidation is a result of Gao Yang's default on a stock pledge repurchase business [1] - The court ruling was made by the Chengdu Financial Court [1] - The company states that this event will not have a significant adverse impact on its production, operations, or financial status [1] Group 2 - The forced sale will not significantly affect the company's governance structure [1]

[Berry Genomics 2025 Semi-Annual Performance Forecast Interpretation](index=1&type=section&id=%E8%B4%9D%E7%91%9E%E5%9F%BA%E5%9B%A02025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) This report interprets Berry Genomics' 2025 semi-annual performance forecast, detailing core financial projections, reasons for performance changes, and audit-related disclosures [Core Performance Forecast Data](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company anticipates a loss for the first half of 2025, with net profit attributable to shareholders projected to be a loss of RMB 22 million to RMB 33 million, a shift from a profit of RMB 9.2628 million in the same period last year Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: 22.00 - 33.00 million RMB | Profit: 9.2628 million RMB | | **Net Profit Excluding Non-Recurring Gains/Losses** | Loss: 24.00 - 35.00 million RMB | Profit: 9.49 million RMB | | **Basic Earnings Per Share** | Loss: 0.0622 - 0.0933 RMB/share | Profit: 0.0262 RMB/share | [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The decline in performance is primarily attributed to external market conditions and internal strategic investments, including increased R&D and domestic substitution efforts, partially offset by non-recurring income - Company's operating revenue and profitability decreased year-on-year due to industry cyclicality and intensified market competition[4](index=4&type=chunk) - The company increased R&D investment, with its GENOisi intelligent agent project reaching cooperation intentions with multiple hospitals, while steadily advancing domestic substitution transformation, which is expected to improve future cost structure[4](index=4&type=chunk) - During the reporting period, the company recorded approximately **RMB 2 million** in non-recurring income, primarily from the disposal of Prenetics shares[4](index=4&type=chunk) [Audit and Risk Disclosure](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5%20%26%20%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company emphasizes that this performance forecast data is a preliminary estimate by the finance department and has not been audited, with final data subject to the official semi-annual report - This performance forecast data is a preliminary estimate by the company's finance department and has not been audited by an auditing firm[3](index=3&type=chunk)[5](index=5&type=chunk) - The company has pre-communicated the performance forecast with the accounting firm, and there are no significant disagreements[3](index=3&type=chunk)

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-034 成都市贝瑞和康基因技术股份有限公司 二、被担保人基本情况 1、名称：北京贝瑞和康生物技术有限公司 8、经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技 术转让、技术推广；信息技术咨询服务；软件开发；健康咨询服务（不含诊疗 服务）；仪器仪表销售；第一类医疗器械销售；化工产品销售（不含许可类化 1 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 6 月 4 日召开第十届董事会第十五次会议审议通过了《关于为全资子 公司提供担保的议案》。公司之全资子公司北京贝瑞和康生物技术有限公司 （以下简称"北京贝瑞"）向中国银行股份有限公司北京首都机场支行（以下 简称"中行首都机场支行"）申请综合授信 3,000 万元，授信期限 1 年。公司 拟为北京贝瑞使用上述授信所形成的债务提供连带责任保证担保。具体内容详 见公司于 2025 年 6 月 6 日在巨 ...

Group 1 - The controlling shareholder, Mr. Gao Yang, has faced forced execution of up to 3,535,214 shares of the company, representing no more than 1% of the total share capital, due to a default in a stock pledge repurchase business [1][2] - The forced execution period is from May 20, 2025, to June 9, 2025, with an execution average price of 13.10 yuan per share [2][3] - Prior to the forced execution, Mr. Gao held 31,988,723 shares (9.0486% of total share capital), which decreased to 28,453,510 shares (8.0486%) after the execution [3] Group 2 - The shares being executed were obtained through a major asset restructuring transaction involving the acquisition of 100% equity of Beijing Berry and Kang Biotechnology Co., Ltd. [2] - The forced execution does not violate any previously disclosed holding intentions or commitments by the controlling shareholder [3][4] - The combined shareholding of Mr. Gao and his concerted action partner, Ms. Hou Ying, decreased from 14.27% to 11.95% during the execution period [3]

成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行实施结果的公告 控股股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"贝瑞基因"）于 2025年5月17日披露了《关于持股5%以上股东所持部分股份被司法强制执行的提示性公 告》（公告编号：2025-025），公司控股股东高扬先生在国信证券股份有限公司（以 下简称"国信证券"）开展的股票质押回购业务发生违约，成渝金融法院裁定强制变 现被执行人高扬先生持有的"贝瑞基因"股票不超过3,535,214股（占公司总股本比例 不超过1%），强制执行截止日期为2025年7月10日（以下简称"本次强制执行"）。 近日，公司收到了控股股东高扬先生出具的《关于持股5%以上股东所持部分股份 被强制执行实施完成的告知函》，在本次强制执行期间，高扬先生累计被强制执行 3,535,213股公司股份，占公司总股本比例不超过1%。 一、强制执行情况 证券代码：000710 证券简称： ...